Abstract
Background Breast cancer is the most common malignancy among women in the United States, with more than 250,000 cases diagnosed each year. Metabolomics, which reflect the aggregate effects of genetics and the environment on an individual’s metabolic state, can shed light on biochemical pathways involved in susceptibility to breast cancer. We investigated associations between pre-diagnostic circulating amino acids-related metabolites and subsequent risk of breast cancer among predominantly premenopausal women.
Methods In 1996-1999, 29,611 women (average age, 44 years) in the Nurses’ Health Study II donated blood samples. Between blood collection and June 2011, 1057 women were diagnosed with breast cancer (average of 8 years after blood collection). Women were predominately premenopausal at the time of blood collection. 207 amino acid and amino acid-related metabolites were profiled with LC-MS/MS. Conditional logistic regression (CLR) was used to estimate odds ratios (ORs) of breast cancer and 95% confidence intervals (CIs). Multivariable analyses evaluating the joint association of all metabolites with breast cancer risk were based on CLR with a lasso penalty (Lasso), CLR with an elastic net penalty (Elastic Net), and Random Forests. We used FDR to account for testing multiple hypotheses.
Results Eleven metabolites were associated with breast cancer risk in CLR models, after adjustment for multiple comparisons (p value < 0.05 and q value < 0.20; creatine had q value > 0.20), 6 of which remained significant after adjustment for breast cancer risk factors (p-value<0.05). Higher levels of six metabolites, including 2-aminohippuric acid, DMGV, kynurenic acid, N2, N2-dimethylguanosine, phenylacetyl glutamine and piperine, were associated with lower breast cancer risk (e.g., piperine: ORsimple (95%CI) = 0.85 (0.78-0.93); ORadjusted (95%CI)=0.84 (0.77-0.92)). Higher levels of asparagine, creatine and 3 lipids (C20:1 LPC, C34:3 PC plasmalogen, C40:7 PE plasmalogen) were associated with increased breast cancer risk (e.g., C40:7 PE plasmalogen ORsimple (95%CI) = 1.14 (1.05-1.25); ORadjusted (95%CI) = 1.11 (1.01-1.22)). Piperine, 2-aminohippuric acid, C40:7 PE plasmalogen and creatine were also selected in multivariable modeling approaches (Lasso, Elastic Net, and Random Forests).
Conclusions Two diet-related metabolites, piperine (responsible for the pungency of pepper) and 2-aminohippuric acid (the glycine conjugate of the tryptophan metabolite anthranilic acid) were inversely associated, while C40:7 PE plasmalogen (a highly unsaturated glycerophospholipid and key component of the lipid bilayer of cells) was positively associated with breast cancer risk among predominately premenopausal women, independent of established breast cancer risk factors. Further validation of the specific metabolite associations with breast cancer risk in independent cohorts is warranted.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is not a clinical trail.
Funding Statement
This study was funded by the National Cancer Institute (R01 CA050385, UM1 CA186107, P01 CA087969, R01 CA49449, U01 CA176726, R01 CA67262).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the institutional review boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon reasonable request.
